The trial is a single arm study in which 40 children with inoperable pontine (brain stem) glioma will be treated with radiation concomitant with nimotuzumab. The primary clinical endpoints in the trial will be progression-free survival with median survival as secondary endpoint.
Clinical sites will be located in Germany, Italy, Belarus and Russia and it is anticipated that recruitment could be complete within approximately 12 months after the start of patient enrolment.
YM BioSciences is also undertaking the clinical development of nimotuzumab in non-small cell lung cancer. While CIMAB SA
YM’s licensor, CIMAB SA and its parent, the Center for Molecular Immunology, are conducting trials with nimotuzumab in glioma, breast, esophageal, uterine cervix, prostate and head and neck cancer.